Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2025
0mins
Merger Approval and Stock Split: Aerovate Therapeutics' stockholders have approved the merger with Jade Biosciences, including a reverse stock split of 1-for-35, which will reduce Aerovate's outstanding shares from approximately 30 million to about 0.8 million.
Post-Merger Trading and Dividend: The combined company's stock will begin trading under the name "Jade Biosciences, Inc." on April 29, with an aggregate cash dividend of $69.6 million payable to stockholders of record as of April 25.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
